Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC

被引：1
|
作者：
El-Ghazzi, Nathan [1 ]
Lavaud, Pernelle [2 ]
机构：
[1] Univ Clermont Auvergne, Med Oncol Serv, Ctr Jean Perrin, Clermont Ferrand, France
[2] Univ Paris Saclay, Dept Med Oncol, Gustave Roussy Canc Campus, Villejuif, France
来源：
BULLETIN DU CANCER | 2021年 / 108卷 / 03期
关键词：
Non-small-cell lung carcinoma; Immunotherapy; Checkpoint immune inhibitors; Chemotherapy; PLATINUM-DOUBLET CHEMOTHERAPY; PLUS IPILIMUMAB;
D O I：
10.1016/j.bulcan.2021.01.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：231 / 233
页数：4
相关论文
共 50 条
  • [41] NIVOLUMAB AND IPILIMUMAB IN FIRST-LINE NON-SMALL-CELL LUNG CARCINOMA (NSCLC): INTERIM PHASE I RESULTS
    Antonia, Scott J.
    Gettinger, Scott
    Chow, Laura Q.
    Juergens, Rosalyn
    Borghaei, Hossein
    Shen, Yun
    Harbison, Christopher
    Chen, Allen C.
    Ready, Neal E.
    Rizvi, Naiyer A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 155 - 155
  • [42] Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)
    Hellmann, M. D.
    Rizvi, N.
    Gettinger, S. N.
    Goldman, J.
    Chow, L. Q.
    Juergens, R.
    Borghaei, H.
    Brahmer, J.
    Shen, Y.
    Harbison, C. T.
    Nathan, F.
    Ready, N. E.
    Antonia, S. J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S632 - S633
  • [43] Nivolumab beyond First-Line (1L) Treatment in Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Sotelo, Miguel
    Chara, Luis
    Riquelme, Alejandro
    Toro, Piedad
    Lopez, Cynthia
    Hernando, Susana
    Caviedes, Edinson
    Aguayo, Cristina
    Bueno, Coralia
    Mielgo Rubio, Xabier
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1340 - S1341
  • [44] Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol
    Janssen, J. C.
    van Dijk, B.
    de Joode, K.
    Aarts, M. J. B.
    van den Berkmortel, F. W. P. J.
    Blank, C. U.
    Boers-Sonderen, M. J.
    van den Eertwegh, A. J. M.
    de Groot, J. W. B.
    Jalving, M.
    de Jonge, M. J. A.
    Joosse, A.
    Kapiteijn, E.
    Kamphuis-Huismans, A. M.
    Naipal, K. A. T.
    Piersma, D.
    Rikhof, B.
    Westgeest, H. M.
    Vreugdenhil, G.
    Oomen-de Hoop, E.
    Mulder, E. E. A. P.
    van der Veldt, Astrid A. M.
    BMC CANCER, 2024, 24 (01)
  • [45] Efficacy of Nivolumab plus Ipilimumab Vs other First-line Treatments for Metastatic NSCLC with PD-L1 <1%: a Network Meta-analysis
    O'Byrne, K.
    Popoff, E.
    Badin, F.
    Lee, A.
    Yuan, Y.
    Goring, S.
    Eccles, L. J.
    Varol, N.
    Waser, N.
    Penrod, J. R.
    Lozano-Ortega, G.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S629 - S630
  • [46] Brigatinib in the first-line treatment of ALK plus metastatic NSCLC: safety and efficacy
    Bronte, Giuseppe
    Cafaro, Alessandro
    Pasini, Luigi
    Priano, Ilaria
    Andrikou, Kalliopi
    Cravero, Paola
    Burgio, Marco Angelo
    Delmonte, Angelo
    Crino, Lucio
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (08) : 809 - 817
  • [47] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
    Peter L. Quon
    Ying Xiao
    Sonja Sorensen
    Amir Abbas Tahami Monfared
    PharmacoEconomics - Open, 2019, 3 : 321 - 331
  • [48] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
    Quon, Peter L.
    Xiao, Ying
    Sorensen, Sonja
    Monfared, Amir Abbas Tahami
    PHARMACOECONOMICS-OPEN, 2019, 3 (03) : 321 - 331
  • [49] COST-EFFECTIVENESS EVALUATION OF SEQUENTIAL TREATMENT STATEGIES FOR TREATMENT NAIVE PATIENTS WITH BRAF MUTANT METASTATIC MELANOMA IN UK: NIVOLUMAB PLUS IPILIMUMAB FIRST-LINE VERSUS DABRAFENIB PLUS TRAMETINIB FIRST-LINE
    Tokarz, A.
    Cai, R.
    Baginska-Dudek, B.
    Yates, G.
    Srinivasan, S.
    Okorogheye, G.
    Palaia, J.
    McDonald, L.
    VALUE IN HEALTH, 2024, 27 (12) : S106 - S106
  • [50] Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting
    Shah, Rajiv
    Reck, Martin
    Grohe, Christian
    Christoph, Daniel Christian
    Buchmeier, Eva Lotte
    Saalfeld, Felix Carl
    Frost, Nikolaj
    Kopp, Hans-Georg
    Faehling, Martin
    Griesinger, Frank
    Roeper, Julia
    Hoffknecht, Petra
    Kuon, Jonas
    Luan, Jingting
    Chesi, Paolo
    Christopoulos, Petros
    Thomas, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345